Atomoxetine Benefits Attention-Deficit/Hyperactivity Disorder and Comorbid Tourette Syndrome
Speaker: Thomas J. Spencer, MD, Associate Professor, Department of Psychiatry, Harvard Medical School, and Assistant Director, Pediatric Psychopharmacology Clinic, Department of Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, Massachusetts
Atomoxetine (Strattera tablet, Lilly), a nonstimulant indicated for attention-deficit/hyperactivity disorder (ADHD), has been shown to be safe, well tolerated, and effective [...]

Donepezil and Severe Alzheimer’s Disease
Speaker: Bengt Winblad, MD, PhD, Professor and Director, Neurotec Department, Division of Geriatrics, Alzheimer’s Disease Research Center, Karolinska Institute and Karolinska University Hospital, Huddinge, Sweden
Donepezil (Aricept canadian, Eisai/Pfizer), well known for its value in the treatment of patients with mild-to-moderate Alzheimer’s disease (AD), has shown substantial benefits in cognition and clinical [...]

New Sumatriptan Formulation for Acute Migraine
Speaker: Roger Cady, MD, Director, Headache Care Center and Primary Care Network, Springfield, Missouri
A new formulation consisting of a fixed-dose, single tablet containing sumatriptan succinate 85 mg with RT Technology (Suma RT) with naproxen sodium 500 mg (NAP) (Suma RT/NAP) (Trexima, GlaxoSmithKline/Pozen) showed superior results in treating acute migraine pain [...]

Rotigotine Patch in Parkinson’s Disease
Speaker: Peter LeWitt, MD, Professor of Neurology and Psychiatry, Wayne State University School of Medicine, Detroit, Michigan, and Clinical Neuroscience Center, South-field, Michigan
The rotigotine transdermal system (Neupro, Schwarz Pharma), a non-ergolinic dopamine receptor agonist, when administered once daily, has been shown to be safe, well tolerated, and effective in patients with [...]

Interferon Beta-1b for Multiple Sclerosis
Speaker: Ludwig Kappos, MD, Professor of Neurology and Clinical Neuroimmunology, Department of Neurology and Research, University of Basel and University Hospital Basel, Basel, Switzerland
In a large-scale European clinical trial, interferon beta-1b (IFN (5-1b) (Betaseron, Schering AG, Germany) was effec­tive, safe, well tolerated, and well accepted for patients with a first clinical [...]